Akebia Therapeutics Inc (NASDAQ:AKBA) shares, rose in value on Thursday, March 27, with the stock price up by 0.52% to the previous day’s close as strong demand from buyers drove the stock to $1.93.
Actively observing the price movement in the last trading, the stock closed the session at $1.92, falling within a range of $1.9 and $1.95. The value of beta (5-year monthly) was 0.944. Referring to stock’s 52-week performance, its high was $2.89, and the low was $0.80. On the whole, AKBA has fluctuated by 7.22% over the past month.
With the market capitalization of Akebia Therapeutics Inc currently standing at about $504.18 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Mar-12.
Projections by analysts suggest varying estimates for the company’s quarterly revenue. Analysts have estimated the company’s revenue for the quarter at 193.8M, with a low estimate of 41.8M and a high estimate of 46.28M. Wall Street analysts also predicted that the company’s y-o-y revenues would reach 44.38M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that AKBA’s technical picture suggests that short-term indicators denote the stock is a Hold on average. However, medium-term indicators have put the stock in the category of 50% Buy while long-term indicators on average have been pointing out that it is a 50% Buy.
The stock’s technical analysis shows that the price of AKBA currently trading nearly -4.91% and -7.02% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 46.48, while the 7-day volatility ratio is showing 6.33% which for the 30-day chart, stands at 8.96%. Furthermore, Akebia Therapeutics Inc (AKBA)’s beta value is 0.88, and its average true range (ATR) is 0.19.
A comparison of Akebia Therapeutics Inc (AKBA) with its peers suggests the former has fared considerably weaker in the market. AKBA showed an intraday change of 0.52% in last session, and over the past year, it shrunk by -12.67%%.
Data on historical trading for Akebia Therapeutics Inc (NASDAQ:AKBA) indicates that the trading volumes over the past 10 days have averaged 8.58 and over the past 3 months, they’ve averaged 3.45 million. According to company’s latest data on outstanding shares, there are 261.23 million shares outstanding.
Nearly 4.10% of Akebia Therapeutics Inc’s shares belong to company insiders and institutional investors own 23.98% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 16.57 million shares as on 2025-03-14, resulting in a short ratio of 5.03. According to the data, the short interest in Akebia Therapeutics Inc (AKBA) stood at 708.00 of shares outstanding as of 2025-03-14; the number of short shares registered in 2025-02-14 reached 14.98 million. The stock has risen by 1.58% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the AKBA stock heading into the next quarter.
